Claire Pomeroy

October 10, 2026

Haemonetics Gets Price Target Hikes Amid Recent Stock Jump. Barrington Research and Mizuho both raised their price targets for Haemonetics to $140, maintaining Outperform ratings. This follows a recent 17.5% jump in the stock, which is now trading near its 52-week high. While some analysts note the current price may not be an ideal entry point, the firm's outlook has improved due to CSL Plasma developments.

October 8, 2026

Concentra Group Hits 52-Week High Amid Medical Services Trends. Concentra Group Holdings, the parent company of Embecta, recently reached a 52-week high, prompting questions about the sustainability of this price movement. This development is relevant to Embecta shareholders as it reflects broader sentiment in the medical services sector. Embecta itself trades with a low trailing P/E of 3.7 and offers a dividend yield of 3.43%, while its stock remains significantly below its 52-week high of $14.91.

October 17, 2026

BDX Revello Stent Trial Success, Revenue Up 5.4%, Earnings Down 34%. The company announced that its Revello stent achieved strong results in the AGILITY trial for peripheral artery disease patients. Revenue rose 5.4% year‑over‑year, but net earnings fell 34.3%, reflecting higher costs or lower margins. The dividend yield sits at 1.59% and analysts see a target of $194, while the stock trades near the top of its 52‑week range.